ENZYME-CATALYZED MUTATION IN BREAST CANCER
Technical Report,01 Aug 2013,31 Jul 2015
UNIVERSITY OF MINNESOTA TWIN CITIES Minneapolis United States
Pagination or Media Count:
The development of breast cancer, including late stage events such as metastasis and drug resistance, requires mutations. The origins of most of these mutations are unknown. We recently implicated the DNA cytosine deaminase APOBEC3B. This Idea Award studies tests the hypothesis that APOBEC3B causes a genome wide hypermutable state and the hypothesis that APOBEC3B alters the epigenome by cytosine deamination and methyl-cytosine deamination mechanisms, respectively. Positive results will be significant because they will delineate a major source of mutations and epigenetic changes in breast cancer, and thereby pave the way for new diagnosticprognostic tests and methods to treat breast cancer by preventing the activity of this enzyme.
- Medicine and Medical Research